Trial · NCT02776917

Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer

NCT02776917, Phase 1, Completed, Barbara Parker, MD; results first posted 2025-08-07

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer. Trials, record NCT02776917. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02776917

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
NCT number: NCT02776917
Status: Completed
Phases: Phase 1
Enrollment: 23 participants, actual
Lead sponsor: Barbara Parker, MD
Conditions: Breast Neoplasms
Interventions: Cirmtuzumab + Paclitaxel
First posted: 2016-05-18
Last updated: 2025-08-07
Results first posted: 2025-08-07

Source ClinicalTrials.gov

Registered outcomes4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Dose-limiting Toxicities During the First 4 Weeks of Treatment	Within 4 weeks of starting study treatment	Clinically significant adverse events per CTCAE Version 4.03 at least possibly related to cirmtuzumab or the combination of cirmtuzumab and paclitaxel during the first four weeks of investigational treatment.
Secondary	Number of Participants With Treatment-emergent Adverse Events	55 weeks	Treatment-emergent adverse events beginning from the start of study treatment to 30 days after study treatment completion or start of new anti-cancer therapy.
Secondary	Objective Tumor Response Rate	55 weeks	Response and progression were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines.
Secondary	Best Tumor Response Rate	12 months	The proportion of patients that achieve a response of stable disease or better as assessed by RECIST v1.1

Source ClinicalTrials.gov

Outcomes4

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Dose-limiting Toxicities During the First 4 Weeks of Treatment	Within 4 weeks of starting study treatment	participants	NUMBER
SECONDARY	Number of Participants With Treatment-emergent Adverse Events	55 weeks	participants	NUMBER
SECONDARY	Objective Tumor Response Rate	55 weeks	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Best Tumor Response Rate	12 months	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Dose-limiting Toxicities During the First 4 Weeks of Treatment	Cirmtuzumab + Paclitaxel	0	participants
Number of Participants With Treatment-emergent Adverse Events	Cirmtuzumab + Paclitaxel	16	participants
Objective Tumor Response Rate	Cirmtuzumab + Paclitaxel	6	Participants
Best Tumor Response Rate	Cirmtuzumab + Paclitaxel	12	Participants

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Cirmtuzumab + Paclitaxel	23
Overall Study	COMPLETED	Cirmtuzumab + Paclitaxel	16
Overall Study	NOT COMPLETED	Cirmtuzumab + Paclitaxel	7

Source ClinicalTrials.gov

Adverse events49

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anemia	Blood and lymphatic system disorders	Cirmtuzumab + Paclitaxel	2	16	3
other	Supraventricular tachycardia	Cardiac disorders	Cirmtuzumab + Paclitaxel	2	16	2
other	Blurred vision	Eye disorders	Cirmtuzumab + Paclitaxel	2	16	2
other	Dry eye	Eye disorders	Cirmtuzumab + Paclitaxel	2	16	2
other	Eye pain	Eye disorders	Cirmtuzumab + Paclitaxel	2	16	2
other	Bloating	Gastrointestinal disorders	Cirmtuzumab + Paclitaxel	2	16	2
other	Constipation	Gastrointestinal disorders	Cirmtuzumab + Paclitaxel	9	16	12
other	Diarrhea	Gastrointestinal disorders	Cirmtuzumab + Paclitaxel	7	16	11
other	Dyspepsia	Gastrointestinal disorders	Cirmtuzumab + Paclitaxel	2	16	2
other	Gastroesophageal reflux disease	Gastrointestinal disorders	Cirmtuzumab + Paclitaxel	2	16	2

1 to 10 of 49Source ClinicalTrials.gov

See all 49 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Cirmtuzumab + Paclitaxel	0	16
Total, other adverse events	Cirmtuzumab + Paclitaxel	16	16
Total, serious adverse events	Cirmtuzumab + Paclitaxel	5	16

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
38408999	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02776917

GET https://conductscience.org/api/trials/v1/NCT02776917/events?page=2

API reference For AI assistants